Weihua Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Weihua Wang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Bo Dai
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
3 shared publications - Da-Qiang Li
Shanghai Cancer Center and Institutes of Biomedical Sciences Shanghai Medical College Fudan University Shanghai 200032 China
3 shared publications - Jared L. Johnson
Department of Cell Biology, Harvard Medical School, Boston, USA
3 shared publications - Jean J. Zhao
Harvard Medical School, Boston, Massachusetts
3 shared publications - Jiachen Wu
Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China
3 shared publications - Johann S. Bergholz
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
3 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-6 from PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis
Figure S1. Bio-ID screening reveals PI3Kβ, but not PI3Kα, as a selective interactor of EPHA2 in PTEN-null cancer cells. Figure S2. PTEN acts as a protein tyrosine phosphatase regulating PI3Kβ- EPHA2 interaction through dephosphorylation of tyrosine-962 (Y962) on PI3Kβ and impact tumorigenesis. Figure S3. Generation of a new antibody to detect phospho-PI3KβY962 levels. Figure S4. PI3Kβ and EPHA2 upregulate pERK/c-MYC and pAKT signaling in PTEN null cancer. Figure S5. Compound library screening identifies dasatinib as an inhibitor of PI3KβY962 phosphorylation that effectively inhibits PTEN-null tumor growth. Figure S6. Phosphorylation of PI3Kβ is a druggable target to treat PTEN-null tumors in vivo.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-6 from PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis
Figure S1. Bio-ID screening reveals PI3Kβ, but not PI3Kα, as a selective interactor of EPHA2 in PTEN-null cancer cells. Figure S2. PTEN acts as a protein tyrosine phosphatase regulating PI3Kβ- EPHA2 interaction through dephosphorylation of tyrosine-962 (Y962) on PI3Kβ and impact tumorigenesis. Figure S3. Generation of a new antibody to detect phospho-PI3KβY962 levels. Figure S4. PI3Kβ and EPHA2 upregulate pERK/c-MYC and pAKT signaling in PTEN null cancer. Figure S5. Compound library screening identifies dasatinib as an inhibitor of PI3KβY962 phosphorylation that effectively inhibits PTEN-null tumor growth. Figure S6. Phosphorylation of PI3Kβ is a druggable target to treat PTEN-null tumors in vivo.
- Open Access
- 17 November 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (3) , 521-540
PTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis
Loss of the tumor-suppressor PTEN drives cancer progression and therapeutic resistance, yet no targeted therapies exist for PTEN-deficient tumors. In this study, we identify a critical druggable mechanism in which PTEN loss induces PI3Kβ phosphorylation for tumorigenesis. Using the BioID interactome, we uncovered a phosphorylation-dependent PI3Kβ–EPHA2 interaction in PTEN-null cells, driven by p-PI3KβY962. PTEN functions as a tyrosine phosphatase that normally dephosphorylates p-PI3KβY962. In PTEN-deficient contexts, enhanced p-PI3KβY962 forms a complex with EPHA2 and SRC, in which both kinases contribute to PI3Kβ phosphorylation, activating oncogenic pERK/c-MYC and pAKT pathways. We developed a selective p-PI3KβY962 antibody detecting p-PI3KβY962 in PTEN-deficient tumors across preclinical models and clinical tumor specimens. Disrupting p-PI3KβY962 suppressed tumor growth in multiple PTEN-null models. Dasatinib, an FDA-approved SRC/EPHA2 inhibitor, effectively reduced p-PI3KβY962 and inhibited tumor progression in PTEN-null but not PTEN wild-type tumors. These findings establish p-PI3KβY962 as a druggable target and biomarker for developing targeted therapy in PTEN-deficient cancers beyond conventional PI3K kinase inhibition. Significance: We revealed a critical new mechanism that PTEN loss induces PI3Kβ phosphorylation and EPHA2/SRC/p-PI3KβY962 complex signaling to drive tumorigenesis. This work directs pharmaceutical development of p-PI3KβY962 inhibitors and biomarker-driven clinical trials repurposing dasatinib for PTEN-deficient solid tumor treatment, with potential to significantly improve outcomes of broad patients with PTEN-deficient tumors.
- 17 November 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (3) , 521-540
Open AccessPTEN Loss Promotes PI3Kβ Phosphorylation and EPHA2/SRC/p-PI3KβY962 Complex Assembly to Drive Tumorigenesis
Loss of the tumor-suppressor PTEN drives cancer progression and therapeutic resistance, yet no targeted therapies exist for PTEN-deficient tumors. In this study, we identify a critical druggable mechanism in which PTEN loss induces PI3Kβ phosphorylation for tumorigenesis. Using the BioID interactome, we uncovered a phosphorylation-dependent PI3Kβ–EPHA2 interaction in PTEN-null cells, driven by p-PI3KβY962. PTEN functions as a tyrosine phosphatase that normally dephosphorylates p-PI3KβY962. In PTEN-deficient contexts, enhanced p-PI3KβY962 forms a complex with EPHA2 and SRC, in which both kinases contribute to PI3Kβ phosphorylation, activating oncogenic pERK/c-MYC and pAKT pathways. We developed a selective p-PI3KβY962 antibody detecting p-PI3KβY962 in PTEN-deficient tumors across preclinical models and clinical tumor specimens. Disrupting p-PI3KβY962 suppressed tumor growth in multiple PTEN-null models. Dasatinib, an FDA-approved SRC/EPHA2 inhibitor, effectively reduced p-PI3KβY962 and inhibited tumor progression in PTEN-null but not PTEN wild-type tumors. These findings establish p-PI3KβY962 as a druggable target and biomarker for developing targeted therapy in PTEN-deficient cancers beyond conventional PI3K kinase inhibition. Significance: We revealed a critical new mechanism that PTEN loss induces PI3Kβ phosphorylation and EPHA2/SRC/p-PI3KβY962 complex signaling to drive tumorigenesis. This work directs pharmaceutical development of p-PI3KβY962 inhibitors and biomarker-driven clinical trials repurposing dasatinib for PTEN-deficient solid tumor treatment, with potential to significantly improve outcomes of broad patients with PTEN-deficient tumors.